Pfm Health Sciences, LP Editas Medicine, Inc. Transaction History

Pfm Health Sciences, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.92 - $9.31 $2.48 Million - $3.34 Million	-358,889 Reduced 81.35%	82,281 $641,000
Q2 2023 Aug 14, 2023	SELL	$6.36 - $11.47 $3.81 Million - $6.88 Million	-599,624 Reduced 57.61%	441,170 $3.63 Million
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $2.99 Million - $4.91 Million	-425,938 Reduced 29.04%	1,040,794 $7.55 Million
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $1.56 Million - $2.48 Million	187,678 Added 14.67%	1,466,732 $13 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $7.9 Million - $12.6 Million	649,370 Added 103.13%	1,279,054 $15.7 Million
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $6.29 Million - $13.4 Million	629,684 New	629,684 $7.45 Million
Q1 2021 May 17, 2021	SELL	$39.71 - $90.58 $1.19 Million - $2.71 Million	-29,900 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $809,393 - $2.52 Million	29,900 New	29,900 $2.1 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.